Patents by Inventor Enrique Iglesias Perez

Enrique Iglesias Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200297840
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 24, 2020
    Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín AGUIAR SANTIAGO, Sonia GONZALEZ BLANCO, Jorge VALDES HERNANDEZ, Mariela VAZQUEZ CASTILLO
  • Publication number: 20080280354
    Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
    Type: Application
    Filed: July 14, 2006
    Publication date: November 13, 2008
    Inventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano
  • Patent number: 7374766
    Abstract: The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: May 20, 2008
    Assignee: Centro de Ingenieria Genetic y Biotechnologia
    Inventors: Julio César Aguilar Rubido, Daniel O. Palenzuela Gardón, Verena L. Muzio González, Gerardo E. Guillén Nieto, Eduardo Pentón Arias, Dagmara Pichardo Díaz, Enrique Iglesias Perez
  • Patent number: 7318927
    Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: January 15, 2008
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano
  • Publication number: 20070275012
    Abstract: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.
    Type: Application
    Filed: October 20, 2004
    Publication date: November 29, 2007
    Inventors: Julio Aguilar Rubido, Enrique Iglesias Perez, Yadira Lobaina Mato, Daymir Garcia Gonzalez, Verena Muzio Gonzalez, Gerardo Guillen Nieto, Nelson Acosta Rivero, Raimundo Ubieta Gomez, Julio Alvarez Obregon, Santiago Duenas Carrera, Carlos Duarte Cano, Peter Vanlandshoot, Luis Herrera Martinez
  • Publication number: 20040073008
    Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
    Type: Application
    Filed: August 27, 2003
    Publication date: April 15, 2004
    Inventors: Enrique Iglesias Perez, Dania M Vazquez Blomquist, Carlos A Duarte Cano
  • Patent number: 6358933
    Abstract: The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: March 19, 2002
    Assignee: Centro de Ingenieria Genetica Y Biotechologia
    Inventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Maria de Jesus Leal Angulo, Dagmara Pichardo Diaz, Enrique Iglesias Perez, Antonieta Herrera Buch, Belquis Sandez Oquendo, Alexis Musacchio Lasa, Diogenes Quitana Vazquez, Lissere Crombet Menedez
  • Patent number: 6355414
    Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: March 12, 2002
    Assignee: Centro de Ingenieria Genetica y Biotechnologia
    Inventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo Piñol